tradingkey.logo
tradingkey.logo

Bayer Says Finerenone Meets Primary Endpoint In Investigational Phase III FIND-CKD Study

ReutersMar 16, 2026 7:32 AM

- BAYER AG BAYGn.DE:

  • KERENDIA® (FINERENONE) MEETS PRIMARY ENDPOINT IN INVESTIGATIONAL PHASE III FIND-CKD STUDY IN PATIENTS WITH NON-DIABETIC CHRONIC KIDNEY DISEASE

  • DEMONSTRATING A STATISTICALLY SIGNIFICANT IMPROVEMENT VERSUS PLACEBO IN ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) SLOPE FROM BASELINE TO MONTH 32 - A SURROGATE ENDPOINT FOR SLOWING KIDNEY DISEASE PROGRESSION

Further company coverage: [BAYGn.DE]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI